reprioritization

AEON Biopharma (NYSE:AEON) on Tuesday said that it had announced plans to advance a single clinical development study in cervical dystonia for ABP-450 injection, utilizing the 351(k) regulatory pathway for biosimilars with BOTOX ((onabotulinumtoxinA)) as the reference product. The company added that under the 351(k) biosimilar regulatory pathway, its plansContinue Reading